OvaGene specializes in the
Women's Health space with a robust proprietary pipeline of tests for cancerous and precancerous conditions.
The OvaGene team deeply cares about women's health and is dedicated to helping gynecologic oncologists improve patient outcomes.
Each patient's cancer is genetically unique. OvaGene testing services provides personalized treatment information.
OvaGene offers gene-based tumor profiling tests including pharmacogenetic analysis, next-gen sequencing and tumor drug response.
OvaGene Point-of-Care Diagnostics
OvaGene is actively developing simple to use, rapid, point-of-care diagnostics tests using the patented Etta-Chip(TM) technology* at our Minnesota research laboratory. With only a drop of blood, the reader-less, disposable Etta-Chip handheld device can identify and quantitate proteins, viruses and nucleic acids within minutes. Our proprietary pipeline under development includes oncology and infectious disease diagnostics. OvaGene is currently pursuing regulatory approvals for our innovative device and is looking forward to commercializing our first point-of-care test in the near future. More information coming soon.
*The Etta-Chip technology was obtained through the Etta Healthcare acquisition. Press Release Download (PDF)
The OvaGene Management Team discusses the mission and purpose behind OvaGene Oncology and the importance of quality, dedication, and commitment to improving patient outcomes.
OvariGENE, EndoGENE, CerviGENE, Kay's Array, OvaTOX, OvaSEQ are trademarks of OvaGene Oncology, Inc.
Copyright 2017 © OvaGene Oncology, Inc.. All rights reserved.